Company profile
Aprea Therapeutics, Inc.
NASDAQ:APREBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EPRENETAPOPT | phase3 | — | 9 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03391050 | phase1_2 | terminated | 2018-01-18 | 2018-08-08 | Aprea Therapeutics | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma |
| NCT03745716 | phase3 | completed | 2019-01-11 | 2020-11-27 | Aprea Therapeutics | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) |
| NCT04419389 | phase1_2 | terminated | 2021-03-02 | 2021-08-23 | Aprea Therapeutics | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) |
| NCT03931291 | phase2 | completed | 2019-09-16 | 2021-08-27 | Aprea Therapeutics | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant |
| NCT04214860 | phase1 | completed | 2019-12-13 | 2022-01-14 | Aprea Therapeutics | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies |
FDA applications (0)
No records yet.